-
-
-
-
-
-
-
Stifel on Travere Therapeutics (TVTX): 'FSGS Increases Risk of CRL, Though Delay/Approval Still Possible'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
Stifel Reiterates Hold Rating on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) Tops Q4 EPS by 17c
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) Announces Proposed Share Offering
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

